Molecules,
Journal Year:
2022,
Volume and Issue:
27(23), P. 8367 - 8367
Published: Nov. 30, 2022
Natural
products
have
been
an
invaluable
and
useful
source
of
anticancer
agents
over
the
years.
Several
compounds
synthesized
from
natural
by
modifying
their
structures
or
using
naturally
occurring
as
building
blocks
in
synthesis
these
for
various
purposes
different
fields,
such
biology,
medicine,
engineering.
Multiple
modern
costly
treatments
applied
to
combat
cancer
limit
its
lethality,
but
results
are
not
significantly
refreshing.
products,
which
a
significant
new
therapeutic
drugs,
currently
being
investigated
potential
cytotoxic
shown
positive
trend
preclinical
research
prompted
numerous
innovative
strategies
order
expedite
clinical
research.
becoming
increasingly
important
drug
discovery
due
high
molecular
diversity
novel
biofunctionality.
Furthermore,
can
provide
superior
efficacy
safety
unique
properties.
The
objective
current
review
is
overview
emergence
treatment
prevention
cancer,
chemosensitizers,
immunotherapeutics,
combinatorial
therapies
with
other
formulations
mechanisms
underlying
Biomolecules,
Journal Year:
2024,
Volume and Issue:
14(2), P. 200 - 200
Published: Feb. 7, 2024
Cancer
has
become
one
of
the
most
multifaceted
and
widespread
illnesses
affecting
human
health,
causing
substantial
mortality
at
an
alarming
rate.
After
cardiovascular
problems,
condition
a
high
occurrence
rate
ranks
second
in
terms
mortality.
The
development
new
drugs
been
facilitated
by
increased
research
deeper
understanding
mechanisms
behind
emergence
advancement
disease.
Numerous
preclinical
clinical
studies
have
repeatedly
demonstrated
protective
effects
natural
terpenoids
against
range
malignancies.
potential
bioactive
investigated
sources
for
their
chemopreventive
chemoprotective
properties.
In
practically
all
body
cells,
signaling
molecule
referred
to
as
signal
transducer
activator
transcription
3
(STAT3)
is
widely
expressed.
that
STAT3
regulates
its
downstream
target
genes,
including
Bcl-2,
Bcl-xL,
cyclin
D1,
c-Myc,
survivin,
promote
growth
differentiation,
cell
cycle
progression,
angiogenesis,
immune
suppression
addition
chemotherapy
resistance.
Researchers
viewed
primary
cancer
therapy
because
crucial
involvement
formation.
This
primarily
focuses
on
directly
indirectly
preventing
expression
tumor
cells.
By
explicitly
targeting
both
vitro
vivo
settings,
it
possible
explain
effect
malignant
this
study,
we
provide
complete
overview
transduction
processes,
carcinogenesis,
related
persistent
activation.
article
also
thoroughly
summarizes
inhibition
certain
terpenoid
phytochemicals,
which
strong
efficacy
several
models.
Molecules,
Journal Year:
2023,
Volume and Issue:
28(5), P. 2070 - 2070
Published: Feb. 22, 2023
Ovarian
cancer
represents
a
major
health
concern
for
the
female
population:
there
is
no
obvious
cause,
it
frequently
misdiagnosed,
and
characterized
by
poor
prognosis.
Additionally,
patients
are
inclined
to
recurrences
because
of
metastasis
treatment
tolerance.
Combining
innovative
therapeutic
techniques
with
established
approaches
can
aid
in
improving
outcomes.
Because
their
multi-target
actions,
long
application
history,
widespread
availability,
natural
compounds
have
particular
advantages
this
connection.
Thus,
effective
alternatives
improved
patient
tolerance
hopefully
be
identified
within
world
nature-derived
products.
Moreover,
generally
perceived
more
limited
adverse
effects
on
healthy
cells
or
tissues,
suggesting
potential
role
as
valid
alternatives.
In
general,
anticancer
mechanisms
such
molecules
connected
reduction
cell
proliferation
metastasis,
autophagy
stimulation
response
chemotherapeutics.
This
review
aims
at
discussing
mechanistic
insights
possible
targets
against
ovarian
cancer,
from
perspective
medicinal
chemists.
addition,
an
overview
pharmacology
products
studied
date
towards
models
presented.
The
chemical
aspects
well
available
bioactivity
data
discussed
commented
on,
attention
underlying
molecular
mechanism(s).
Future Journal of Pharmaceutical Sciences,
Journal Year:
2024,
Volume and Issue:
10(1)
Published: June 17, 2024
Abstract
Background
Carbazoles
are
an
important
class
of
heterocyclic
aromatic
compounds
that
contain
nitrogen
atom
in
the
ring.
They
have
a
large-conjugated
system,
attractive
“electrical
and
charge-transport
properties”,
ability
to
efficiently
incorporate
different
functional
groups
into
structurally
inflexible
carbazolyl
Main
text
Carbazole
derivative
ECCA
acts
as
anticancer
agent
by
reactivating
P53
molecular
signaling
pathway;
similarly,
some
other
derivatives
carbazole
show
antifungal
activity
acting
on
RAS-MAPK
pathway.
also
their
effect
inflammation
inhibiting
p38
mitogen-activated
protein
kinase
pathway
stopping
conversion
DAXX
ASK-1.
By
modifying
AKT
through
boosting
phosphatase
brain,
they
anti-Alzheimer’s
translocating
GLUT4
these
effective
against
diabetes.
Conclusion
After
exploring
literature
carbazole,
it
was
found
has
immeasurably
great
potential
for
treatment
various
diseases
nucleus
leads
synthesized
which
used
pharmacological
activities.
So
there
is
need
explore
newer
drugs.
Frontiers in Toxicology,
Journal Year:
2025,
Volume and Issue:
7
Published: May 1, 2025
Background
In
2022,
approximately
2.3
million
new
cases
of
female
breast
cancer
and
670,000
related
deaths
worldwide
despite
significant
advancements
in
conventional
treatments.
BobyGuard
C
(BGC)
is
a
novel
polyherbal
nutraceutical
formulated
from
five
plants,
selected
for
their
antioxidant,
anticancer,
anti-inflammatory
nutritional
properties
to
be
used
management.
This
study
aimed
characterize
its
physicochemical,
nutritional,
phytochemical
as
well
assess
safety
through
acute
sub-acute
oral
toxicity
studies
Wistar
rats.
Methods
Thecomposition
BGC
was
analyzed
macronutrients,
minerals,
phytochemicals
using
standard
methods.
Antioxidant
activity
assessed
DPPH,
TAC
FRAP
assays,
while
antiproliferative
evaluated
the
MTT
assay
on
MDA-MB
231
MCF-7
cell
lines.
Acute
(single
5,000
mg/kg
dose
with
14
days
observation)
(daily
administration
784,
1,568,
3,136
28
days)
rats
followed
OECD
guidelines.
Results
found
rich
proteins
(38.36
g/100
g),
carbohydrates
(59.70
essential
minerals
such
magnesium
(60,066.67
µg/100
it
free
toxic
heavy
metals.
Several
bioactive
compounds,
including
diosgenin,
diosbulbin
H,
β-carotene,
Bafoudiosbulbin
G
catechin
were
identified
BGC.
Phytochemical
analysis
revealed
high
levels
phenols
(9,783.48
mg
GAE/100
flavonoids
(47.72
QuE/100
alkaloids
(106.14
berberine
eq/100
contributing
strong
antioxidant
(DPPH
inhibition:
90.39%).
exhibited
effects
cells,
highlighting
potential
anticancer
activity.
tests
showed
no
mortality
at
mg/kg,
an
LD
50
exceeding
this
dose.
28-day
repeated-dose
study,
doses
up
mg/kg/day
resulted
some
dependent
hematological
biochemical
changes
but
histopathological
abnormalities
observed
indicating
lower
doses.
Conclusion
nutritionally
formulation
potent
potential,
demonstrating
favorable
profile
(784
mg/kg).
BMC Complementary Medicine and Therapies,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Jan. 11, 2024
Abstract
Background
Breast
cancer
(BC)
is
the
most
frequent
malignancy
in
world.
Chemotherapy
(CT)
a
common
treatment
for
BC
but
accompanied
by
toxicity
and
side
effects.
Shenqi
Fuzheng
Injection
(SFI)
an
adjuvant
therapy
with
promising
results
improving
efficacy
reducing
clinical
studies.
This
overview
of
systematic
reviews
meta-analysis
(SRs/MAs)
aimed
to
summarize
benefits
evaluate
quality
evidence
supporting
SFI
as
CT
BC.
Methods
A
search
SRs/MAs
randomized
controlled
trials
(RCTs)
on
was
performed
searching
PubMed,
Web
Science,
EMbase,
Cochrane
Library,
CNKI,
Wanfang,
VIP,
SinoMed
databases
from
inception
October
1,
2022.
The
evaluated
using
AMSTAR-2,
PRISMA
2020,
ROBIS,
GRADE
two
reviewers.
corrected
covered
area
(CCA)
used
quantify
degree
duplication
original
SRs/MAs.
Finally,
quantitative
analysis
RCTs
conducted
RevMan
5.4
software.
study
registered
PROSPERO,
CRD42022377290.
Results
Six
including
61
5593
patients
were
included
this
study.
Studies
published
between
2015
2019,
ranged
7–49,
sample
sizes
ranging
336–1989.
found
that
improved
response
rate
(RR=1.37,
95%
CI=1.28,
1.46;
P
<0.00001)
KPS
score
(RR=1.66,
CI
1.54,
1.79,
In
terms
immune
function,
CD3+
(SMD=1.51,
0.91,
2.10;
<0.00001),
CD4+
(SMD=1.87,
1.18,
2.56;
CD4+/CD8+
(SMD=0.86,
0.48,
1.23;
NK
cell
levels
(SMD=0.94,
0.63,
1.24;
group
better
than
those
alone.
Adverse
reactions
following
showed
reduced
incidence
leukopenia
(RR=0.53,
0.46,
0.62;
gastrointestinal
(RR=0.48,
0.39,
0.58;
<0.00001).
However,
‘very
low’
‘moderate’
42
outcomes,
without
high-quality
them,
limited
mainly
deficiencies
design
(42/42,
100.00%),
inconsistency
(19/42,
45.24%),
publication
bias
(41/42,
97.62%),
inaccuracy
(3/42,
7.14%).
unsatisfactory
ROBIS
lack
registration
protocols,
explanation
inclusion
basis
RCTs,
description
funding
sources
studies,
incomplete
strategy
screening
process,
addressing
heterogeneity
sensitivity,
reporting
potential
conflicts
interest.
Conclusion
Adjuvant
had
lower
risk
adverse
events.
methodology
are
generally
low,
highlighting
need
greater
attention
during
implementation.
More
objective
studies
needed
verify
decision-making
